Hypocalcaemia in patients with metastatic bone disease treated with denosumab
Jean-Jacques Body(National Cancer Centre Japan), Paul J. Kostenuik(Amgen (United States)), Alison Stopeck(National Cancer Centre Japan), Henry G. Bone(University of Arizona), Adam J. Shaywitz(Amgen (United States)), Catherine Van Poznak(University of Michigan), Toshimi Takano(The Cancer Institute Hospital), Huei Wang(National Taiwan University), Toni Ibrahim(Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori), Fred Saad(Centre Hospitalier de l’Université de Montréal), Ronaldo Damião(Hospital Universitário Pedro Ernesto), Neal D. Shore(Carolina Urologic Research Center), David H. Henry(Pennsylvania Hospital), Richard H. De Boer(National Cancer Centre Japan), Ada Braun(National Cancer Centre Japan), Oswaldo L. Bracco(Amgen (United States)), Allan Lipton(National Cancer Centre Japan), Karim Fizazi(Université de Lille)
Cited by 150
Related Papers
Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
|New England Journal of Medicine|2017|6k
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
|New England Journal of Medicine|2014|3k
Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
|New England Journal of Medicine|2012|2.8k
Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3
|Journal of Clinical Oncology|2016|1.6k
Denosumab Compared With Zoledronic Acid for the Treatment of Bone Metastases in Patients With Advanced Breast Cancer: A Randomized, Double-Blind Study
|Journal of Clinical Oncology|2010|1.6k